SecBot SecBot
8-K ·Filed Nov 6, 2026

GKOS

GLAUKOS Corp
NEUTRAL
Impact 3/10
Horizonmonths Processed10d 19h ago SEC0001193125-26-450710
8-K context-dependent: Items 7.01
Actionable Insight • Neutral

Monitor upcoming quarterly results for execution on iDose TR and Epioxa commercial launches, which are key to sustaining the 2026/2027 revenue guidance. The pipeline milestones (iDose TRIO Phase 3b, Retina XR Phase 2a data) are the next catalysts.

DirectionNeutral
Confidencehigh
Horizonmonths

Drugs in focus

GKOS drug pipeline →

iDose TREX

● Neutral Named in this 8-K
Impact
Phase
Phase 2b/3
Time to market
Unknown; Phase 2b/3 trials typically take 2-4 years to complete, so potential approval would likely be 2028-2030 at earliest, assuming positive data.
Next catalyst
None dated

What to watchMonitor for interim or topline data readouts from the Phase 2b/3 program, which could serve as a catalyst. The next meaningful update may come at a major ophthalmology conference. Meanwhile, iDose TR commercial adoption trends and quarterly earnings are the primary near-term drivers for GKOS stock.

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$224.41
T+0 close · Nov 6, 2026 · via day close
Latest settled
+9.50%
T+5 · $245.72
Vs SPY
+6.90%
α at T+5
Next horizon
T+20
in 20d
  1. T+0 · Nov 6 $224.41entry
  2. T+1 · 8d ago +6.39%α +4.02% · $238.74
  3. T+5 · 4d ago +9.50%α +6.90% · $245.72
  4. T+6 · todayOpen
  5. T+20 · in 20d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Glaukos filed an 8-K to post a November 2026 investor presentation. The presentation reiterates the company's pipeline strategy across interventional glaucoma and keratoconus, highlights the iDose TR and Epioxa launches, and reaffirms revenue guidance of $1,000M for 2026/2027. No new material financial data or guidance changes were disclosed.

Key Facts

  • Investor presentation dated November 2026 posted as Exhibit 99.1
  • Revenue guidance midpoint of $1,000M for 2026/2027 as of the Q3 2026 earnings call on 10/28/2026
  • Q3 2026 gross margin of 88%
  • $340M cash and equivalents; no debt as of 9/30/2026
  • 30% topline growth in 2025; 20% 10-year revenue CAGR
  • 14 disclosed pipeline programs; 12 currently commercialized products
  • Epioxa (epi-on CXL for keratoconus) commercially available since March 2026
  • iDose TR FDA-approved for re-administration (Jan 2026); Phase 3b study for iDose TRIO enrolled
  • Retina XR IVT multi-kinase inhibitor program (GLK-401) Phase 2a first-in-human trial enrollment complete
  • iLution blepharitis program in Phase 2 with completed patient enrollment

Financial Impact

No new financial data; revenue guidance midpoint of $1,000M for 2026/2027 reiterated from prior earnings call

revenue

Risk Factors

  • Commercial adoption of iDose TR and Epioxa may underperform expectations
  • Clinical trial delays or negative data for pipeline programs (iDose TRIO, Retina XR, iLution)
  • Reimbursement and payer coverage hurdles for new procedural pharmaceuticals
  • Competitive pressure from other MIGS and CXL therapies

Market Snapshot

Exchange
NYSE
Sector
Surgical & Medical Instruments & Apparatus
Analyst Consensus
90% bullish (20 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-450710
Document: gkos-ex99_1.htm0001193125-26-450710
Document: 0001193125-26-450710-index-headers.html0001193125-26-450710
Document: 0001193125-26-450710-index.html0001193125-26-450710
Document: 0001193125-26-450710.txt0001193125-26-450710

Track record

16 reports on GKOS

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $242.67 Now $244.88 +0.91% settles Nov 23
  2. Nov 12, 20264d ago 144 Neutral 3/10 Entry $245.72 Now $244.88 −0.34% settles Nov 20
  3. Nov 6, 202610d ago 8-K Neutral 3/10 Viewing Entry $224.41 to $245.72 Now $244.88 +9.12% ▲ +9.50% +6.90% vs SPY
  4. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $224.41 to $245.72 Now $244.88 +9.12% ▲ +9.50% +6.90% vs SPY
  5. Nov 4, 202612d ago 144 Neutral 2/10 Entry $246.70 to $247.16 Now $244.88 −0.74% ▲ +0.19% +1.10% vs SPY
  6. Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $246.70 to $247.16 Now $244.88 −0.74% ▲ +0.19% +1.10% vs SPY
  7. Oct 30, 202617d ago 144 Neutral 3/10 Entry $237.60 to $224.41 Now $244.88 +3.06% ▼ −5.55% −2.85% vs SPY
  8. Oct 28, 202619d ago 8-K Bullish 6/10 Entry $242.48 to $219.98 Now $244.88 +0.99% ▼ −9.28% −4.55% vs SPY
  9. Aug 13, 202613w ago Insider Cluster Neutral 3/10 Entry $184.53 to $184.89 Now $244.88 +32.70% ▲ +0.20% +1.56% vs SPY
  10. Aug 11, 202613w ago Insider Cluster Neutral 2/10 Entry $186.63 to $189.55 Now $244.88 +31.21% ▲ +1.56% +2.01% vs SPY
Showing 10 of 16

US Market Status

Market Closed · Opens in 6h 37m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 6, 2026